New data bolsters Sarepta gene therapies for two deadly muscle diseases

Sarepta Therapeutics is providing the latest evidence suggesting that two similar, experimental gene therapies it’s developing might help treat two deadly genetic diseases.

As with previous updates to the two programs for Duchenne muscular dystrophy and a form of limb-girdle muscular dystrophy, the results, presented at the Annual Congress of the World Muscle Society, aren't definitive.